PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

PharmaShots Weekly Snapshots (October 31 – November 04, 2022)

PharmaShots Weekly Snapshots (October 31 – November 04, 2022)

November 4, 2022

Pfizer and BioNTech Reports P-II/III Trial Results of Omicron BA.4/BA.5-Adapted Bivalent Booster for COVID-19

Pfizer and BioNTech Reports P-II/III Trial Results of Omicron BA.4/BA.5-Adapted Bivalent Booster for COVID-19

November 4, 2022

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) Receives the EC’s Approval for the Prevention of RSV Lower Respiratory Tract Disease in Infants

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) Receives the EC’s Approval for the Prevention of RSV Lower Respiratory Tract Disea...

November 4, 2022

Pfizer and BioNTech Initiate P-I Study of mRNA-Based Combination Vaccine for the Treatment of COVID-19 and Influenza

Pfizer and BioNTech Initiate P-I Study of mRNA-Based Combination Vaccine for the Treatment of COVID-19 and Influenza

November 4, 2022

Ascentage Pharma to Present P-II Study Results of Lisaftoclax (APG-2575) for Chronic Lymphocytic Leukemia at ASH 2022

Ascentage Pharma to Present P-II Study Results of Lisaftoclax (APG-2575) for Chronic Lymphocytic Leukemia at ASH 2022

November 4, 2022

$Pfizer’s Elranatamab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma$

Pfizer’s Elranatamab Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple M...

November 4, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us